This darling of the Covid era has given back considerable gains in recent years, but it could be on the verge of a turnaround.
Get this delivered to your inbox, and more info about our products and services.
The investment bank upgraded the pharma stock to overweight from equal weight.
Regeneron's deep pipeline of potentially successful drugs helps to offset competitive risks in other areas.
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of…
The investment bank upgraded the pharmaceutical name to buy from neutral.
Frank Cappelleri of CappThesis breaks down the bullish technical backdrop for this pharma-related stock.
After a recent acquisition, the company has renewed focus and increased scale. It also could see upside from strong cash flow and…
